Evercore ISI Initiates Coverage on OnKure Therapeutics (NASDAQ:OKUR)

Stock analysts at Evercore ISI began coverage on shares of OnKure Therapeutics (NASDAQ:OKUR) in a report released on Wednesday, MarketBeat reports. The firm set an “outperform” rating on the stock.

Other analysts have also issued research reports about the stock. HC Wainwright decreased their target price on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Oppenheimer lowered their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, March 11th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $32.33.

OnKure Therapeutics Price Performance

Shares of OnKure Therapeutics stock opened at $2.50 on Wednesday. The business has a 50 day moving average price of $3.93 and a 200 day moving average price of $8.62. The company has a market capitalization of $33.59 million, a P/E ratio of -0.20 and a beta of 0.35. OnKure Therapeutics has a 1 year low of $2.42 and a 1 year high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.51). As a group, research analysts expect that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Institutional Investors Weigh In On OnKure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC acquired a new position in shares of OnKure Therapeutics in the 4th quarter valued at about $75,000. OMERS ADMINISTRATION Corp purchased a new stake in OnKure Therapeutics during the 4th quarter worth $104,000. Walleye Capital LLC purchased a new stake in shares of OnKure Therapeutics in the fourth quarter worth about $116,000. Two Sigma Advisers LP acquired a new stake in OnKure Therapeutics in the fourth quarter valued at approximately $122,000. Finally, Shay Capital LLC purchased a new stake in OnKure Therapeutics during the 4th quarter worth $129,000. 90.98% of the stock is currently owned by institutional investors and hedge funds.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.